NEWPORT BEACH, Calif. ― At the OCTANe Ophthalmology Technology Summit here, Bill Carpou, CEO of OCTANe, discusses the goals of the meeting and how OCTANe is working to grow businesses and move startup companies from an idea to a successful business platform.
Author: Healio ophthalmology
J&J CEO confirms company’s commitment to ophthalmology
NEWPORT BEACH, Calif. — Johnson & Johnson is “absolutely committed” to ophthalmology and is actively looking at ways to increase its presence in the space due to the large unmet needs of an aging population, Alex Gorsky, CEO of Johnson & Johnson, said here. In a wide-ranging interview at the OCTANe Ophthalmology Technology Summit with Jim Mazzo, global president of ophthalmic devices at Carl Zeiss Meditec, Gorsky was asked if he sees other areas in ophthalmology in which the company could further expand or if he was focused fully on (Read more...)
Novartis reports $11.5 billion in quarterly sales
Novartis reported net sales of $11.5 billion in the first quarter compared with $11.6 billion in the same quarter of 2016, according to a press release. Net income was reported at $1.7 million, a decrease from $2 million in 2016’s first quarter.
Near vision can be optimized with scleral micro-inserts
Finding a solution to presbyopia, a condition that affects nearly 90 million Americans and 1.7 billion people worldwide, has long been the holy grail in ophthalmology. Most of our current surgical approaches to presbyopia, including monovision LASIK an…
Ziv-aflibercept improves visual acuity, macular thickness in refractory DME
Patients with refractory diabetic macular edema treated with ziv-aflibercept experienced improved visual acuity and macular thickness, with no adverse ocular or systemic side effects reported in the retrospective case series.The case series included 34…
PUBLICATION EXCLUSIVE: Young woman who went blind in one eye presents years later with symptoms in fellow eye
A 21-year-old Hispanic woman presented to the University of New Mexico with a 1-month history of worsening flashes of light and scotomas in her left superior field of vision.Regarding her medical and ocular history, the patient had previously been diagnosed with a “generalized vasculitis.” When she was 14 years old, she developed joint pain in her wrists, ankles and knees. Within a week of the onset of the arthralgias, she also lost vision in the right eye and has since only seen bare light perception in that eye. She was (Read more...)
Senate health care bill takes slower approach to House bill, expert concerns persist
The Senate health care bill, released to the public today, maintains much from the version the House passed May 4, 2017, but presents some key changes such as a slower phase out of Medicaid expansion and funding cost-sharing exchange plans for 2 years.“The most important take away is that both the House and Senate versions make efforts to stabilize the insurance market — the non-employer, individual insurance markets — in various ways,” Kristine Blackwood, from the international law firm Arnold & Porter Kaye Scholer LLP, told Healio.com. “There should largely (Read more...)
Two iStent injects and topical travoprost reduce IOP, medication use through 18 months
The implantation of two second-generation iStent inject devices and postoperative topical prostaglandin in eyes with open-angle glaucoma reduced mean IOP and medication use at 18 months, according to a study. The prospective, nonrandomized, open-label …
Marketing authorization application filed in Europe for Durasert 3-year uveitis treatment
A marketing authorization application has been filed to the European Medicines Agency for the approval to market Durasert 3-year treatment for posterior segment uveitis, according to a pSivida press release.The treatment has seen its primary efficacy e…
NovaBay reports $4 million quarterly loss
NovaBay Pharmaceuticals announced a $4 million net loss in the first quarter of 2017 compared with a net loss of $5.1 million in the same quarter of last year. Research and development costs declined from $0.9 million in 2016 to $0.1 million this quart…
Avedro names new chief financial officer
Thomas E. Griffin will join Avedro as its new chief financial officer. “Tom’s financial acumen combined with his significant experience in the medical technology industry for both private and publicly held companies will be a tremendous asset,” Avedro Chief Executive Officer Reza Zadno, PhD, said in a company press release.
AMA supports efforts to improve substance abuse disorder coverage
Experts from four leading nonprofits in the addiction field have determined that existing legislation does not adequately protect insurance coverage of substance abuse disorders, according to a press release.
FDA commissioner calls for public input on lifting generic barriers
In introducing the FDA’s Drug Competition Action Plan, the commissioner announced his intent to assess ways FDA rules may be misused to create obstacles against generic drug access and competition; the organization plans to hold a meeting on July 18, 2017, to solicit input from the public.“Too many patients are being priced out of the medicines they need,” Scott Gottlieb, MD, commissioner of the FDA, wrote in the FDA’s blog. “While FDA doesn’t have a direct role in drug pricing, we can take steps to help address this problem by (Read more...)
CMS proposes rule to increase flexibility, reduce burdens
CMS recently issued a proposed rule to update the Quality Payment Program as required by the Medicare Access and CHIP Reauthorization Act of 2015 to simplify reporting requirements, ensure fiscal sustainability and high-quality care within Medicare, and offer support for clinicians in 2018, according to a press release.The move quickly drew praise from the AMA, which noted the measure’s emphasis on “high-quality, high-value care” and flexibility.
Lampalizumab reduces geographic atrophy lesion progression
Monthly lampalizumab, a potential therapy for patients with geographic atrophy secondary to age-related macular degeneration, reduced lesion area progression by 20% compared to a sham control, according to results of the MAHALO study. The phase 2 clini…
State medical licensing board questions may discourage physicians from addressing their mental health
Medical license application questions are still not treating mental and physical illness the same, and this could be impacting a physician’s decision to seek treatment for mental disorders, according to findings recently published in Family Medicine. “There had been some studies many years ago that also looked at how states treat mental health and physical health. I expected that there would be quite a bit of change since our study was done quite a number of years later,” Katherine J. Gold, MD, MSW, MS, department of family medicine, University of (Read more...)
Red light technology improves tear break-up in dry eye
The at-home use of a red light therapy was shown to affect the meibomian gland secretions and alleviate the symptoms of dry eye, according to a report at the Association for Research and Vision in Ophthalmology annual meeting.The prospective study meas…
Eylea sales up in first quarter
Eylea net product sales totaled $854 million in the United States for the first quarter, up 9% over the same quarter last year, according to a Regeneron press release.In the first quarter of 2016, Eylea (aflibercept) injection sales totaled $781 million.
VIDEO: Brimonidine investigated for preserving vision in glaucoma and retina disease
BALTIMORE — At the Association for Research in Vision and Ophthalmology meeting here, James Burke, PhD, of Allergan, discusses research into brimonidine in preserving vision in both glaucoma and retina disease.
Neurotech’s macular telangiectasia treatment sees positive phase 2 results
A phase 2 trial of NT-501 found the therapy had a beneficial effect in patients with macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.Patients in the multicenter, randomized clinical trial had a statistically s…